NCT00201903

Completed

The Roles of Tissue Factor in Malignant Gliomas

Ontario Clinical Oncology Group (OCOG)Source

Compare

Other study identifiers

Sponsor study identifier

OCOG-2003-TFsubstudy

Study Type

observational

Actual enrollment (reported)

30

Locations

2 countries

Sites

6

Timeline

Study Start

January 2004

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

Not reported

Date not reported

Study Completion

October 2006

Actual (reported)

Brief Summary

To explore the relationship between tissue factor levels, tumour progression, activation of blood coagulation and venous thromboembolism with malignant glioma

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Actual enrollment (reported): 30 participants
Study completion date: October 2006
Actual (reported)
Listed locations: 2 countries · 6 sites

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
January 2004
Date type not reported
This date has not been verified as actual or estimated.
First Submitted
September 13, 2005
Actual (reported)
First Posted
September 20, 2005
Actual (reported)
Study Completion
October 2006
Actual (reported)

Last Updated: April 6, 2017
Status Verified: May 2007
Last Update Submitted: April 5, 2017

Conditions

Brain Tumors Venous Thromboembolism

Keywords

venous thromboembolismbrain tumoursgliomatissue factorblood coagulationtumour progressionlow molecular weight heparin

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

participation in PRODIGE
adult patients
newly diagnosed, biopsy-confirmed grade III/IV malignant gliomas
undergone craniotomy or stereotactic biopsy \> 2 days and \< 4 weeks before

You may not qualify if:

Sponsors & Collaborators

Ontario Cancer Research Network
Research networkcollaborator
Ontario Clinical Oncology Group (OCOG)
Otherlead

Study Sites (6)

Henry Ford Hospital

Detroit, Michigan, 48202, United States

Huntsman Cancer Institute

Salt Lake City, Utah, 84112-5550, United States

Cross Cancer Institute

Edmonton, Alberta, T6G 1Z2, Canada

CancerCare Manitoba

Winnipeg, Manitoba, R3E 0V9, Canada

Toronto-Sunnybrook Regional Cancer Centre

Toronto, Ontario, M4N 3M5, Canada

Princess Margaret Hospital

Toronto, Ontario, M5G 2M9, Canada

MeSH Terms

Conditions

Venous ThromboembolismBrain NeoplasmsGliomaThrombosisDisease Progression

Condition Hierarchy (Ancestors)

ThromboembolismEmbolism and ThrombosisVascular DiseasesCardiovascular DiseasesCentral Nervous System NeoplasmsNervous System NeoplasmsNeoplasms by SiteNeoplasmsBrain DiseasesCentral Nervous System Diseases

Study Officials

Agnes Lee, MD
Hamilton Health Sciences and McMaster University
STUDY CHAIR
William Geerts, MD
Sunnybrook Health Sciences Centre
PRINCIPAL INVESTIGATOR
Mark Levine, MD
Ontario Clinical Oncology Group (OCOG)
PRINCIPAL INVESTIGATOR
James Perry, MD
Toronto Sunnybrook Regional Cancer Centre
PRINCIPAL INVESTIGATOR

Enrollment

30 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Time Perspective: PROSPECTIVE
Sponsor Type: OTHER

Study Record Dates

First Submitted

September 13, 2005

First Posted

September 20, 2005

Study Start

January 2004

Date type not reported

This date has not been verified as actual or estimated.

Terminated

NCT00418691

Effects of Methylphenidate Versus Sustained Release Methylphenidate on Cognitive Functioning

Phase 3Terminated

NCT00810784

Evaluation of Venous Thromboembolism (VTE) Prophylaxis in Medically Ill Patients

Completed

NCT00229801

Evaluation of Kidney Function in Children With Brain Tumors

Not ApplicableWithdrawn

NCT00182221

Safety of a Diagnostic Strategy With D-Dimer Testing for PE

Phase 3Completed

NCT00584883

A Phase I Study of ABT 510 for Newly Diagnosed Glioblastoma Multiforme

Phase 1Completed

NCT01988675

MRI Study of Radiation-Induced Damage to White Matter and Blood-Brain-Barrier

Completed

have known hereditary thrombophilia

are receiving experimental antiangiogenic therapy

Contact the study team to confirm eligibility.

Nervous System Diseases

Neoplasms, Neuroepithelial

Neuroectodermal Tumors

Neoplasms, Germ Cell and Embryonal

Neoplasms by Histologic Type

Neoplasms, Glandular and Epithelial

Neoplasms, Nerve Tissue

Disease Attributes

Pathologic Processes

Pathological Conditions, Signs and Symptoms

Janusz Rak

Hamilton Health Sciences and McMaster University

PRINCIPAL INVESTIGATOR

Jeffrey Weitz, MD

Hamilton Health Sciences and McMaster University

PRINCIPAL INVESTIGATOR

Study Completion

October 2006

Actual (reported)

Last Updated

April 6, 2017

Record last verified: 2007-05

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT00201903
Data provider: ClinicalTrials.gov
Source updated: 2017-04-06
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:35:45 UTC

Locations

CA(4)US(2)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Study Completion

Conditions

Keywords

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

Study Sites (6)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

Source record

Locations